47 results on '"Camez, Anne"'
Search Results
2. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial
3. Long-Term Safety and Effectiveness of Adalimumab for Moderate to Severe Psoriasis: Results from 7-Year Interim Analysis of the ESPRIT Registry
4. Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease
5. Adalimumab Induces Deep Remission in Patients With Crohn's Disease
6. Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: Results from the CARE trial
7. Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn's Disease: Data From the EXTEND Trial
8. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease
9. Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis
10. Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis
11. Adalimumab in Active and Inactive, Non-Infectious Uveitis : Global Results from the VISUAL I and VISUAL II Trials
12. Adalimumab in Active and Inactive, Non-Infectious Uveitis : Global Results from the VISUAL I and VISUAL II Trials
13. Lack of Effect of 12-Week Treatment with Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients with Moderate to Severe Chronic Plaque Psoriasis
14. Adalimumab in Active and Inactive, Non-Infectious Uveitis: Global Results from the VISUAL I and VISUAL II Trials
15. Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III
16. Corticosteroid-Related Adverse Events Systematically Increase with Corticosteroid Dose in Noninfectious Intermediate, Posterior, or Panuveitis
17. Adalimumab in patients with active and inactive, non-infectious uveitis: VISUAL I and VISUAL II trials
18. Adalimumab in Patients with Active Noninfectious Uveitis
19. Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis
20. Mo1296 Quality of Life for Patients With Deep Remission vs. Clinical Remission and Deep Remission vs. Absence of Mucosal Ulceration: 3-Year Data From CHARM/ADHERE
21. Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohnʼs disease: Results from CARE
22. Achievement of Early Deep Remission Is Associated with Lower Rates of Weekly Dosing for Adalimumab-Treated Patients with Crohnʼs Disease: Data from EXTEND
23. Adalimumab is Effective for Inducing Clinical Remission at Week 4 Regardless of Baseline Corticosteroid Use: Pooled Analysis of Four Clinical Trials
24. Achievement of Early Deep Remission Predicts Better Long-Term Outcomes for Adalimumab-Treated Patients with Crohnʼs Disease: Data from EXTEND
25. Effect of Disease Duration on “Deep Remission”: Results from the EXTEND Trial
26. 41a Prediction of Long-Term Clinical Remission for Adalimumab-Treated Patients With Crohn's Disease by Identification of Appropriate Dichotomizing Points for SES-CD
27. T1239 Adalimumab Treatment Results in Deep Remission for Patients With Moderate to Severe Ileocolonic Crohn's Disease: Results From EXTEND
28. M1049 Japanese Patients With Moderately to Severely Active Crohn's Disease Experience Improved Quality of Life With Adalimumab Treatment
29. Sustained Remission with Adalimumab Therapy in Japanese Patients with Moderately to Severely Active Crohnʼs Disease
30. Quality-of-life Improvements in Adalimumab-treated Patients with Mucosal Healing: Results from the EXTEND Trial
31. Adalimumab Downregulates Markers of Inflammation in Patients with Moderate to Severe Ileocolonic Crohnʼs Disease: The Histologic Substudy of EXTEND
32. 751e Adalimumab Induces and Maintains Mucosal Healing in Patients with Moderate to Severe Ileocolonic Crohn's Disease – First Results of the Extend Trial
33. S1131 Adalimumab Reduces Extraintestinal Manifestations in Patients with Crohn's Disease in the Care Trial
34. S1144 Adalimumab Induces Sustained Fistula Healing in Both Anti-TNF-Naïve and Anti-TNF-Experienced Patients with Crohn's Disease: The Care Trial
35. T1215 Subanalysis of Remission Rates By Duration of Disease in Adalimumab-Treated Patients with Crohn's Disease: the Care Trial
36. Adalimumab Effectiveness in TNF-Antagonist-Naïve Patients and in Infliximab Nonresponders with Crohnʼs Disease
37. Efficacy and Safety of Adalimumab for the Treatment of Japanese Patients with Moderately to Severely Active Crohnʼs Disease
38. Effect of Concomitant Steroid or Immunosuppressant Treatment on Adalimumab Response in Patients with Crohnʼs Disease
39. Efficacy and Safety of Adalimumab Treatment in Patients with Moderate to Severe Psoriasis: A Double-Blind, Randomized Clinical Trial
40. Efficacy and safety of propafenone sustained release in the prophylaxis of symptomatic paroxysmal atrial fibrillation (The European Rythmol/Rytmonorm Atrial Fibrillation Trial [ERAFT] Study)
41. Recombinant hirudin (lepirudin) for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction
42. Recombinant hirudin: A specific thrombin inhibiting anticoagulant for hemodialysis
43. Hirudin, contrary to heparin, does not induce platelet adhesion to blood clots and extracellular matrix in vitro
44. Efficacy and Safety of Adalimumab Treatment in Patients with Moderate to Severe Psoriasis: A Double-Blind, Randomized Clinical Trial
45. Subcutaneous Recombinant Hirudin (HBW 023) Versus Intravenous Sodium Heparin in Treatment of Established Acute Deep Vein Thrombosis of the Legs: a Multicentre Prospective Dose-ranging Randomized Trial
46. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial.
47. Adalimumab in Active and Inactive, Non-Infectious Uveitis: Global Results from the VISUAL I and VISUAL II Trials.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.